Drug Transporter (DT) Information

General Information of DT
DT ID DTD0029
Gene Name SLCO1A2
Protein Name Organic anion transporting polypeptide 1A2
Gene ID
6579
UniProt ID
P46721
TCDB ID
2.A.60.1.14
3D Structure

Modelled DT Structure

Method: multi-sequence alignment based machine learning

Detail: Structure Info

Synonyms OATP-A; OATP1A2; Organic anion-transporting polypeptide 1; SLC21A3; SLCO1A2; Sodium-independent organic anion transporter; Solute carrier family 21 member 3; Solute carrier organic anion transporter family member 1A2
DT Family Organo Anion Transporter (OAT) Family ;
Function This Na(+)-independent transporter mediates the transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids. Selectively inhibited by the naringin.
Disease(s) Atrial fibrillation [ICD-11: BC81.3]
Chronic myelogenous leukemia [ICD-11: 2A20.0]
Dry eye disease [ICD-11: 9A79]
Dyslipidaemias [ICD-11: 5C8Z]
High blood pressure [ICD-11: BA00]
Human immunodeficiency virus infection [ICD-11: 1C62.Z]
Leukemia [ICD-11: 2A60-2B33]
Medical abortion [ICD-11: JA00.1]
Ehlers-Danlos syndrome [ICD-11: LD28.1]
Endogenous Substrate(s) Cholate; Luciferin; Thyroid hormones; Dehydroepiandrosterone sulfate; Tauroursodeoxycholate; Thyroxine
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:          39 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Acebutolol
 Approved Drug Info Ventricular premature beats BC70 [1]
Atenolol
 Approved Drug Info High blood pressure BA00 [1]
Atorvastatin
 Approved Drug Info Hyperlipidaemia 5C8Z [2]
Celiprolol
 Approved Drug Info High blood pressure BA00 [3]
Chlorambucil
 Approved Drug Info Chronic lymphocytic leukemia 2A82.0 [4]
Cholic acid
 Approved Drug Info Synthesis disorders 5C52.10 [5]
Ciprofloxacin
 Approved Drug Info Seizure 8A68 [1]
Darunavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [6]
Dehydroepiandrosterone sulfate
 Approved Drug Info Dyspareunia GA12 [7]
Dinoprostone
 Approved Drug Info Medical abortion JA00.1 [8]
Enalapril
 Approved Drug Info High blood pressure BA00 [9]
Enoxacin
 Approved Drug Info Gonorrhea 1A70-1A7Z [10]
Estrone sulfate
 Approved Drug Info Menopausal symptoms MF32 [11]
Fexofenadine
 Approved Drug Info Allergic rhinitis CA08.0 [2]
Gatifloxacin
 Approved Drug Info Bacterial infections 1A00-1H0Z [10]
Grepafloxacin
 Approved Drug Info Chronic bronchitis CA20.1 [10]
Hydroxyurea
 Approved Drug Info Chronic myelogenous leukemia 2A20.0 [12]
Imatinib
 Approved Drug Info Gastrointestinal stromal tumor 2B5B [13]
Labetalol
 Approved Drug Info Hypertension BA00 [3]
Levofloxacin
 Approved Drug Info Gram-positive & negative bacteria infections 1A00-1H0Z [10]
Levothyroxine
 Approved Drug Info Hypothyroidism 5A00.2 [14]
Lifitegrast
 Approved Drug Info Dry eye disease 9A79 [15]
Liothyronine
 Approved Drug Info Hypothyroidism 5A00.2 [14]
Lomefloxacin
 Approved Drug Info Bacterial infections 1A00-1H0Z [10]
Methotrexate
 Approved Drug Info Leukemia 2A60-2B33 [16]
Montelukast
 Approved Drug Info Asthma CA23 [17]
Nadolol
 Approved Drug Info High blood pressure BA00 [3]
Norfloxacin
 Approved Drug Info Urinary tract infections GC08 [10]
Ouabain
 Approved Drug Info Heart failure BD1Z [18]
Pitavastatin
 Approved Drug Info Primary hyperlipidemia and mixed dyslipidemia 5C8Z [19]
Pitavastatin calcium
 Approved Drug Info Dyslipidaemias 5C8Z [19]
Probenecid
 Approved Drug Info Hyperuricaemia 5C55.Y [20]
Quinolones
 Approved Drug Info Tuberculosis 1B1Z [21]
Rocuronium
 Approved Drug Info Muscle relaxant XM31L2 [22]
Rosuvastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [23]
Saquinavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [24]
Sotalol
 Approved Drug Info Maintenance of normal sinus rhythm BC81.3 [3]
Telmisartan
 Approved Drug Info High blood pressure BA00 [25]
Trospium chloride
 Approved Drug Info Overactive bladder GC50.0 [26]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            5 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Atrasentan
 Phase 3 Drug Info Endothelial dysfunction BE2Z [27]
Glycocholic acid
 Phase 3 Drug Info Bile acid synthesis defect 5C52.11 [28]
BQ-123
 Phase 2 Drug Info ST-Elevation myocardial infarction BA41.0 [28]
Talinolol
 Phase 1 Drug Info Gastrointestinal motility disorder DE2Z [29]
Tauroursodeoxycholate
 Phase 1 Drug Info Asthma CA23 [5]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            6 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Aminohippuric acid
 Withdrawn Drug Info Renal function tests MG02 [30]
Rhodamine 123
 Discontinued in Phase 1 Drug Info Prostate cancer 2C82 [31]
TR-14035
 Discontinued in Phase 1 Drug Info Multiple scierosis 8A40 [32]
Sodium taurocholate
 Preclinical Drug Info Type 2 diabetes 5A11 [5]
Urea
 Preclinical Drug Info Dermatological disease EA00-EM0Z [12]
Taurocholic acid
 Terminated Drug Info Type 2 diabetes 5A11 [33]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Bile acid unspecific N.A. EM Info Identified using healthy people enrolled into 12-wk weight loss intervention [34]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:          14 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1A2 Km = 13.6 microM [16]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-OATP1A2 Km = 16.1 microM [33]
Estrone sulfate Approved Drug Info Oocytes-OATP1A2 Km = 9.6 microM [33]
Estrone sulfate Approved Drug Info Oocytes-OATP1A2 Km = 59 microM [35]
Fexofenadine Approved Drug Info Human cervical cancer cell line (Hela)-OATP1A2 Km = 6.4 microM [36]
Levofloxacin Approved Drug Info Oocytes-OATP1A2 Km = 136 microM [10]
Levothyroxine Approved Drug Info Oocytes-OATP1A2 Km = 8 microM [14]
Liothyronine Approved Drug Info Oocytes-OATP1A2 Km = 6.5 microM [14]
Methotrexate Approved Drug Info Oocytes-OATP1A2 Km = 457 microM [16]
Ouabain Approved Drug Info Oocytes-OATP1A2 Km = 5500 microM [35]
Pitavastatin calcium Approved Drug Info Oocytes-OATP1A2 Km = 3.4 microM [19]
Rosuvastatin Approved Drug Info Human cervical cancer cell line (Hela)-OATP1A2 Km = 2.6 microM [23]
Saquinavir Approved Drug Info Oocytes-OATP1A2 Km = 36.4 microM [24]
Trospium chloride Approved Drug Info Primary human bladder urothelium cells (HBU) Km = 34.9 microM [26]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            5 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Sodium taurocholate Preclinical Drug Info Oocytes-OATP1A2 Km = 60 microM [5]
Taurocholic acid Terminated Drug Info Human embryonic kidney cells (HEK293)-OATP1A2 Km = 15.9 microM [33]
Taurocholic acid Terminated Drug Info Human liver cancer cells (HepG2)-OATP1A2 Km = 64 microM [37]
Taurocholic acid Terminated Drug Info Oocytes-OATP1A2 Km = 60 microM [5]
Bromsulphthalein Investigative Drug Info Oocytes-OATP1A2 Km = 20 microM [5]
References
1 Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
2 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
3 Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
4 Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004;44:137-66.
5 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
6 P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull. 2009 Sep;32(9):1588-93.
7 Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36.
8 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
9 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
10 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
11 Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci. 2011 Jul 17;43(4):297-307.
12 Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
13 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
14 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
15 Clinical Pharmacology and Biopharmaceutics review(s)
16 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
17 Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol. 2011 May;51(5):751-60.
18 Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J. 2000 Jan 1;345 Pt 1:115-20.
19 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
20 Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22.
21 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.14)
22 Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther. 1999 Oct;291(1):147-52.
23 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
24 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
25 Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006 Jul;34(7):1109-15.
26 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
27 Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
28 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
29 Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res. 2009 Mar;26(3):560-7.
30 Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E390-8.
31 Characterization of rhodamine-123 as a tracer dye for use in in vitro drug transport assays. PLoS One. 2012;7(3):e33253.
32 Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035. Pharm Res. 2006 Nov;23(11):2646-56.
33 Identification of multiple binding sites for substrate transport in bovine organic anion transporting polypeptide 1a2. Drug Metab Dispos. 2013 Mar;41(3):602-7.
34 Determinants of postprandial plasma bile acid kinetics in human volunteers. Am J Physiol Gastrointest Liver Physiol. 2017 Oct 1;313(4):G300-G312.
35 Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J Hepatol. 1996 Nov;25(5):733-8.
36 OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71.
37 Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology. 1996 May;23(5):1053-60.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.